Nephros Announces First Quarter 2021 Financial Results Conference Call
04/26/2021 - 07:30 AM
SOUTH ORANGE, NJ, April 26, 2021 (GLOBE NEWSWIRE) -- via NewMediaWire Nephros
Participants may dial into the call as follows:
Upon joining, please ask to be joined into the Nephros conference call.
A replay of the call can be accessed until May 13, 2021 at 1-877-344-7529 or 1-412-317-0088 for international callers and entering replay access code: 10153586.
An audio archive of the call will be available shortly after the call on the Nephros investor relations page at https://investors.nephros.com/events/
About Nephros
Nephros is a leading water technology company in medical and commercial water purification and pathogen detection, headquartered in the USA. Our diverse team of passionate employees is dedicated to advancing point-of-use water safety through education, product solutions, and emergency outbreak response management.
For more information about Nephros, please visit www.nephros.com
Investor Relations Contact: ksmith@pcgadvisory.com www.pcgadvisory.com
Company Contact: andy@nephros.com www.nephros.com
NEPH Rankings
#361 Ranked by Stock Gains
NEPH Stock Data
Industry
Surgical and Medical Instrument Manufacturing
Sector
Manufacturing
Tags
Medical Specialties, Health Technology, Manufacturing, Surgical and Medical Instrument Manufacturing
About NEPH
nephros is a commercial stage medical device company that develops and sells high performance liquid purification filters. nephros filters capture contaminants as small as 5 nanometers in size; they minimize exposure to a wide variety of bacteria, viruses, fungi, parasites, and endotoxins. nephros filters use a proprietary hollow fiber technology; the hollow fiber design enables the filters to optimize the three elements critical to filter performance: • filtration – as low as 5 nanometers • flow rate – minimal disruption • filter life – up to 12 months nephros was founded in 1997, by healthcare professionals affiliated with columbia university medical center, initially to address the needs of chronic renal failure patients. the company has developed an alternative to current hemodialysis therapy known as mid-dilution hemodiafiltration (mid-hdf). nephros’ proprietary blood purification technologies enable mid-hdf to be offered to chronic renal failure patients. nephros mid-dilution fil
